Anavex Life Sciences delays filing quarterly report for June 30, 2026 quarter
Reuters2026/08/10 21:00- Anavex filed a late notice for its Form 10-Q for the quarter ended June 30, 2026, missing the Aug. 10, 2026 deadline.
- Delay tied to added time needed to prepare and review the filing amid a board special committee review linked to the CEO termination.
- Christopher Missling was terminated as CEO on April 30, 2026; Terrie Kellmeyer was appointed interim CEO on May 4, 2026.
- Also reported as delinquent on its Form 10-Q for the quarter ended March 31, 2026.
- No significant change in results of operations anticipated versus the prior-year period.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The South Korean stock market is brewing bottom-fishing opportunities: foreign capital sell-off slows, Korean won strengthens, and KOSPI 200 valuation drops to the first decile in ten years.
After a deleveraging phase and concentrated foreign selling, the South Korean stock market is experiencing a dual turning point in both valuation and technical indicators. On September 8, the Korean stock index broke above its short-term downtrend line and closed above the 50-day moving average for the first time. The forward P/E ratio of KOSPI 200 is only 6.2x, ranking in the first percentile of the past ten years. Analysts believe this extreme discount provides strong downside protection.
The collective strong rebound of Asian currencies
OTC Markets Group approves Apptly Health for OTCQB trading
Crypto prices
More
